UOC
KPTI icon

UBS O'Connor’s Karyopharm Therapeutics KPTI Stock Holding History

UBS O'Connor’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-26,667
Closed -$30K – 405
2024
Q4 		$30K Buy
+26,667
New +$322K ﹤0.01% 376
2024
Q2 		– Sell
-21,720
Closed -$33.9K – 591
2024
Q1 		$33.9K Buy
21,720
+1,720
+9% +$30.2K ﹤0.01% 454
2023
Q4 		$7.5K Hold
20,000
– – ﹤0.01% 463
2023
Q3 		$60K Buy
+20,000
New +$449K ﹤0.01% 479

Other funds holding KPTI

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

UBS O'Connor's KPTI Position: Q2 2025 in Review

UBS O'Connor sold out of Karyopharm Therapeutics (KPTI) in Q2 2025, closing a stake of 23,640 shares — an estimated $88.4K sold.

UBS O'Connor first reported a position in KPTI in Q1 2015 and held it in 13 quarters. The position peaked at $2.31M in Q1 2023. 50 funds tracked by Wall St. Rank hold KPTI as of Q2 2025.

  • UBS O'Connor reported no remaining Karyopharm Therapeutics position as of Q2 2025 after selling out during the quarter.
  • UBS O'Connor sold 23,640 Karyopharm Therapeutics shares in Q2 2025, an estimated $88.4K.
  • UBS O'Connor first reported a position in Karyopharm Therapeutics in Q1 2015 and held it in 13 quarters.
  • UBS O'Connor's Karyopharm Therapeutics position peaked at $2.31M in Q1 2023.
  • 50 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q2 2025.

Based on UBS O'Connor's 13F filing for Q2 2025, filed 14 Aug 2025.